This summary covers key developments in health news, including Mitsubishi Pharma's bidding war, legal actions involving J&J ...

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...

Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...

The Centers for Medicare & Medicaid Services (CMS) has mandated Medicare Advantage insurers to provide coverage for Biogen's amyotrophic lateral sclerosis (ALS) medication, Qalsody. This directive ...

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...

CMS has reportedly directed Medicare Advantage plan providers to cover Biogen's drug Qalsody for ALS following reports it was ...

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...

Analysts have recently evaluated Biogen and provided 12-month price targets. The average target is $241.79, accompanied by a ...

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Check Out Our Latest Report on Biogen Biogen Stock Performance Shares of NASDAQ BIIB opened at $160.63 on Friday. Biogen Inc. has a 1 year low of $153.62 and a 1 year high of $268.30. The company ...